Eisai Restructures U.S. Operations
News Mar 10, 2011
Eisai, Inc., a U.S. subsidiary of Eisai Co., Ltd., plans to restructure its operations, cutting approximately 20% of its workforce across all U.S. functions, resulting in the loss of 600 positions by April 1, 2011. The restructuring is part of Eisai’s global strategic plan for FY2011-2015, to become a more efficient and focused organization.
The company plans to focus on advancing its oncology portfolio and launch new neuroscience assets. Eisai’s U.S. operations include R&D, manufacturing, sales and marketing, and administrative functions.
“This restructuring is essential to our remaining competitive in this rapidly changing environment,” said Lonnel Coats, president and chief executive officer of Eisai Inc. “It will enable us to continually make the necessary investments in our science, our people and ultimately our human health care (hhc) mission, while ensuring an adequate return to our shareholders.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019